119th Congress

H.Res. 1285

Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

1. Introduced
2. In committee
3. Agreed to

Sponsor

Diana DeGette(D-CO)

Introduced

May 14, 2026

Policy area

Health

Committees

House Committee on Energy and Commerce

Official text

Introduced in House · Congress.gov page

Cosponsors (54)

Original cosponsors (12)

• Ayanna Pressley (D-MA)
• Becca Balint (D-VT)
• Brittany Pettersen (D-CO)
• Eleanor Holmes Norton (D-DC)
• Jennifer L. McClellan (D-VA)
• Jesús G. "Chuy" García (D-IL)
• Katherine M. Clark (D-MA)
• Maxine Dexter (D-OR)
• Nydia M. Velázquez (D-NY)
• Paul Tonko (D-NY)
• Seth Moulton (D-MA)
• Wesley Bell (D-MO)

Summary

Roll-call votes

No recorded votes on this bill.

Actions

• May 14, 2026 · House
  Referred to the House Committee on Energy and Commerce.
• May 14, 2026 · House
  Submitted in House